Last checked at 21 Sep 2023 14:37
Diaceutics PLC - Directorate Changes
Graham Paterson appointed as an independent Non-Executive Director
Charles Hindson retiring as a Non-Executive Director
Belfast and London, 21 September 2023 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharmaceutical industry, today announces the appointment of Graham Paterson as an independent Non-Executive Director of Diaceutics PLC effective 1 October 2023. The Company also announces the retirement of Charles Hindson as a Non-Executive Director of Diaceutics PLC also effective 1 October 2023.
Graham Paterson is a highly experienced business leader and Non-Executive Director. He is currently a Non-Executive Director of Invesco Perpetual UK Smaller Companies Investment Trust plc, Baillie Gifford US Growth Trust plc and Chairman of Mobeus Income and Growth 4 VCT plc. He has held senior executive roles in a number of companies including TopQ Software Ltd and SL Capital Partners.
Graham Paterson is a Chartered Accountant and a member of the Institute of Chartered Accountants of Scotland and holds an Honours degree in Economics and Management from the University of St. Andrews. On appointment, Graham Paterson will become Chair of the Audit and Remuneration Committees of Diaceutics PLC.
Deborah Davis, Diaceutics' Non-Executive Chair, commented: "I would like to thank Charles for his hard work, dedication and much valued counsel during the past four years and wish him well in his future endeavours.
I warmly welcome Graham to the board of Diaceutics, his extensive leadership and board experience will contribute significantly to our work and support our growth as we become the primary commercialisation partner for pharma and biotech companies launching precision medicines."
Information required to be disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies:
The following information is disclosed in relation to Graham Douglas Paterson, aged 52:
Current Directorships | Past Directorships (previous 5 years) |
Baillie Gifford US Growth Trust Plc
Invesco Perpetual UK Smaller Companies Investment Trust Plc
Mobeus Income and Growth 4 VCT Plc
Datactics Ltd
Substantive Research Ltd
The Wemyss Development Company Ltd
GDP 1 Ltd
| The IDco Ltd
Octopus VCT 4 Plc
Berry Starquest Limited
|
Graham Paterson does not hold any ordinary shares or share options in the Company.
Save for the information disclosed above, there is no other information to be disclosed under Schedule 2(g) of the AIM Rules.
Enquiries:
Diaceutics PLC | Tel: +44 (0)28 9040 6500 |
Peter Keeling, Chief Executive Officer Ryan Keeling, Chief Innovation Officer Nick Roberts, Chief Financial Officer | investorrelations@diaceutics.com |
Stifel Nicolaus Europe Limited (Nomad & Broker) | Tel: +44 (0)20 7710 7600 |
Ben Maddison | |
Nick Harland Kate Hanshaw | |
Alma PR | Tel: +44 (0)20 3405 0205 |
Caroline Forde | diaceutics@almapr.co.uk |
Matthew Young | |
Kinvara Verdon |
About Diaceutics
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.
We provide the world's leading pharma and biotech companies with an end-to-end commercialization solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostic Network®.